Open company graph database — free web & API
Login

Japan Abiomed Inc.

日本アビオメッド株式会社Abiomed Japan CorporationAlias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
0
§01

Basic information

BASIC
Head office
12th Floor, Muromachi Toho Mitsui Building, 2-2-1 Nihonbashi Muromachi, Chuo-ku, Tokyo 103-0022, Japan
Chief executive
Hideyuki Yamamoto
Capital
300,000,000 JPY (3 100 millionJPY)
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

5
Impella CP SmartAssistImpella 5.5 SmartAssistImpella ControllerAccessoriesImpella Connect
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

41 EVENTS

Abiomed was established in 1981 with the aim of developing the world's first artificial heart.Sources

Abiomed was founded to develop the first artificial heart.Sources

Celebrating the 10th anniversary of Abiomed's founding.Sources

Abiomed celebrates its 10th anniversary.Sources

Announced BVS 5000, the first left ventricular assist device approved by the US FDA for BTR (Bridge to Recovery).Sources

BVS 5000® becomes the first ventricular assist device ever approved by the U.S. FDA for bridge-to-recovery.Sources

Clinical use of the total replacement artificial heart AbioCor began, implanted in the first patient.Sources

Physicians treat the first AbioCor patient with the first totally implantable artificial heart.Sources

Under new CEO Mike Minogue, Abiomed transitioned to products focused on heart recovery. AB5000 received FDA approval for BTR (Bridge to Recovery).Sources

Under new CEO Mike Minogue, Abiomed shifts focus to heart recovery; AB5000™ receives U.S. FDA approval for bridge-to-recovery.Sources

Acquired Impella CardioSystems based in Aachen, Germany. Impella obtained CE mark and began sales in Europe.Sources

Abiomed acquires Impella CardioSystems in Aachen, Germany.Sources

Impella 2.5 received FDA 510(k) clearance. PROTECT I clinical trial completed.Sources

Impella 2.5 heart pump receives U.S. FDA 510(k) clearance; Abiomed completes PROTECT I clinical trial.Sources

AB Portable Driver received FDA approval, and the first patient with AB5000 was discharged. Impella 5.0 and Impella LD (not approved in Japan) received FDA 510(k) clearance.Sources

Impella 5.0® and Impella LD® heart pumps receive U.S. FDA 510(k) clearance; AB Portable Driver receives U.S. FDA approval and the first patient is discharged on AB5000™.Sources

Launched the new Impella Controller (Automated Impella Controller). Achieved non-GAAP revenue. Results of RECOVER I clinical trial published in Journal of Thoracic and Cardiovascular Surgery.Sources

The new Automated Impella Controller™ (AIC) is now available; Abiomed achieves non-GAAP profitability; RECOVER I clinical trial results published in the Journal of Thoracic and Cardiovascular Surgery.Sources

Results of the PROTECT II randomized controlled trial published in Circulation. Impella CP received FDA 510(k) clearance. Abiomed co-founded MVPvets to support employment of veterans in the medical device industry.Sources

Results of the PROTECT II randomized controlled trial published in Circulation, the journal of the American Heart Association; Impella CP heart pump receives U.S. FDA 510(k) clearance; Abiomed co-founds MedTechVets.Sources

Started RECOVER RIGHT clinical trial for Impella RP (not approved in Japan) in the US. Established Japan Abiomed Inc.Sources

RECOVER RIGHT clinical trial begins in the U.S. for the Impella RP heart pumpSources

Abiomed announced acquisition of ECP, a medical device company based in Berlin, Germany. Over 20,000 patients treated with Impella.Sources

Abiomed announces the acquisition of ECP, a medical device company based in Berlin, Germany; Abiomed surpasses 20,000 patients supported with ImpellaSources

FDA approved Impella 2.5 for elective and urgent high-risk PCI.Sources

U.S. FDA grants PMA approval to Impella 2.5 for elective and urgent high-risk proceduresSources

All Impella products for left heart support received PMA approval for treatment of cardiogenic shock. Impella 2.5, Impella 5.0, and Impella Controller obtained medical approval in Japan. Impella CP received PMA for expanded indication for high-risk PCI in the US.Sources

Entire family of Abiomed Impella left side heart pumps receive U.S. FDA PMA approval; Impella 2.5® and Impella 5.0® receive regulatory approval in Japan; U.S. FDA grants expanded PMA approval to Impella CP® for high-risk PCI proceduresSources

New, expanded Abiomed headquarters officially opened in Duxbury, Massachusetts. Over 50,000 patients treated with Impella. First patient enrolled in STEMI DTU pilot randomized trial. FDA approved Impella RP (not approved in Japan) for right heart failure. Sales of Impella 2.5 and Impella 5.0 began in Japan.Sources

Abiomed celebrates the grand opening of its newly-expanded headquarters in Danvers, MA; surpasses 50,000 patients treated with Impella; first patient enrolls in STEMI DTU pilot randomized controlled trial; U.S. FDA grants PMA approval for Impella RP for right heart failure; physicians treat first patient with Impella in JapanSources

The number of patients treated with Impella has exceeded 100,000 worldwide. The first patient was treated with Impella 5.5 SmartAssist in Germany. SmartAssist technology received regulatory approval from authorities. The US FDA approved the expansion of Impella's indication for use in high-risk PCI. Announced success of the STEMI DTU pilot randomized controlled trial.Sources

Abiomed surpasses 100,000 patients treated with Impella; German physicians treat first patient with Impella 5.5 with SmartAssist; SmartAssist technology receives regulatory approval; Abiomed launches Women's Initiative for Heart Recovery; U.S. FDA grants approval for expanded indications for Impella; investigators announce successful STEMI DTU pilot randomized controlled trial resultsSources

The first patient was treated with Impella 5.5 SmartAssist in the United States. Sales of Impella CP began in Japan. The number of patients treated with Impella in Japan exceeded 1,000. The first patient was enrolled in the pivotal randomized controlled trial of STEMI DTU.Sources

First U.S. patients are treated with Impella 5.5 with SmartAssist; 1,000th patient treated with Impella in Japan; first patient enrolls in STEMI DTU™ pivotal randomized controlled trialSources

Acquired Breethe's OXY-1 System and treated the first patient with ECMO technology (not approved in Japan, photo on the left). Treated the first patient with Impella ECP (not approved in Japan, photo on the right). The number of patients treated with Impella exceeded 150,000 worldwide. The US FDA granted EUA (Emergency Use Authorization) for Impella treatment in certain COVID-19 patients. The US FDA approved data streaming from Impella control devices, enabling AI algorithm analysis.Sources

Abiomed acquires Breethe™ and its OXY-1 System and treats first patients with ECMO technology; physicians treat first patients with the 9 French Impella ECP; Abiomed surpasses 150,000 patients treated with Impella; U.S. FDA grants EUA for Impella to provide therapy to certain COVID-19 patients; U.S. FDA approves data streaming from the Impella consoleSources

The first patient was enrolled in the PROTECT IV randomized controlled trial. The number of patients treated with Impella exceeded 200,000. The US FDA designated Impella ECP, the world's smallest heart pump (not approved in Japan), as a Breakthrough Device. Impella RP with SmartAssist (not approved in Japan) received the highest level of approval from the US FDA for treatment of right heart failure. Abiomed acquired preCARDIA (not approved in Japan), which aims to improve prognosis in heart failure patients. Regulatory approval for Impella 5.5 SmartAssist was obtained in Japan.Sources

First patient enrolls in the PROTECT IV randomized controlled trial; Abiomed surpasses 200,000 patients treated with Impella; U.S. FDA grants breakthrough device designation to Impella ECP; U.S. FDA grants highest level of approval to Impella RP with SmartAssist; Abiomed acquires preCARDIASources

Abiomed acquired by Johnson & Johnson; Abiomed surpasses 250,000 patients treated with Impella; U.S. FDA grants 510(k) clearance for Impella Low Profile Sheath; Physicians treat the first patient with Impella BTR; All post-approval studies for Impella heart pumps completed successfully; Physicians treat first patient with Impella 5.5 in JapanSources

Pivotal Impella ECP Study expands enrollment to three New Jersey hospitals; Analysis shows potential for more complete revascularizations with Impella during HRPCI; Reached 300,000+ patients treated globallySources

A groundbreaking randomized controlled trial published in the New England Journal of Medicine demonstrated a mortality benefit from Impella use in AMICS shock due to STEMI; Celebrated 25 years of Impella and heart recovery; U.S. FDA expanded the usage of left-sided Impella devices to specific pediatric patients; Surpassed 350,000 patients treated globallySources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information9010001157532
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
日本アビオメッド株式会社
Trade name (kana)
ニホンアビオメッド
Name in English
Corporation type
301
Address
〒103-0022 東京都中央区日本橋室町2丁目2番1号
Postal code
1030022
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2019-03-28
Change date
2016-10-17
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
2468552
METI gBizINFO9010001157532
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
9010001157532
Trade name
日本アビオメッド株式会社
Trade name (kana)
ニホンアビオメッド
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都千代田区西神田3丁目5番2号
Postal code
1010065
Prefecture
東京都
Prefecture code
13
City or district
千代田区
City code
101
Street address
西神田3丁目5番2号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役 山本 英右
Capital
Employees
126
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
E:製造業
Date established
2013-12-10
Unified government qualification - grade
|B|B|
Unified government qualification - business items
219|308
Update date
2026-10-02
Key information
9010001157532
§09

Sources & updates

SOURCES
↑